
Targeted Oncology
Advertisement
Articles by Targeted Oncology









Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.












Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.









Advertisement
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
3
FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
4
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
5
